Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsGood practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement.Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklistsIntravenous antimicrobial therapy in the hospital-at-home setting: data from the Spanish Outpatient Parenteral Antimicrobial Therapy Registry.Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.Predictors of Unplanned Hospitalization in Patients Receiving Outpatient Parenteral Antimicrobial Therapy Across a Large Integrated Healthcare NetworkRisk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug UsersComparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient settingInfluence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in EuropeAn unsupported preference for intravenous antibiotics.Antimicrobial Stewardship from Policy to Practice: Experiences from UK Antimicrobial Pharmacists.The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia.Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.Acute dental infections managed in an outpatient parenteral antibiotic program setting: prospective analysis and public health implications.Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidencePrediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy.Outpatient parenteral antimicrobial therapy (OPAT) in the Republic of Ireland: results of a national survey.Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center.Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement.Oritavancin: A Long-Half-Life Lipoglycopeptide.Outpatient parenteral antimicrobial therapy with ceftriaxone for acute tonsillopharyngitis: efficacy, patient satisfaction, cost effectiveness, and safety.Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach.Alternatives to ward admission from the emergency department.WHAT IS THE MAXIMUM TEMPERATURE REACHED IN ELASTOMERIC DEVICES UNDER SIMULATED OPAT CONDITIONS?Patient Characteristics and Outcomes of Outpatient Parenteral Antimicrobial Therapy: A Retrospective Study.Patient retention of training in self-administration of intravenous antibiotic therapy in an outpatient parenteral antibiotic therapy service.Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service.Optimising patient safety when using elastomeric pumps to administer outpatient parenteral antibiotic therapy.Utilizing a Modified Care Coordination Measurement Tool to Capture Value for a Pediatric Outpatient Parenteral and Prolonged Oral Antibiotic Therapy Program.Diabetic foot infection: Antibiotic therapy and good practice recommendations.Outpatient Parenteral Antimicrobial Therapy in Pediatric Medicaid Enrollees.Economic evaluation of outpatient parenteral antimicrobial therapy: a systematic review.False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia.Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial).Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis.Diagnosis and management of cellulitis and erysipelas.How is income generated by outpatient parenteral antibiotic treatment (OPAT) in the UK? Analysis of payment tariffs for cellulitis.
P2860
Q26752922-83BC2545-3FDC-43ED-B5AE-01C3D82E4B8AQ27687541-2EB74911-D60E-40A6-81CE-E736EF83F4F1Q28088622-65F4EB96-475B-4543-868B-EDC978866917Q31058008-3CE77C4B-6E2B-48CF-B261-F17021EE1837Q33797925-EBAE6736-06E3-4E48-A52D-35F53C16BE18Q33806376-D6D0FD5D-EDB2-49F6-B492-02522C3B3D66Q33862093-0EBF583C-C01D-47FA-A5A9-DC5510527A0CQ33947743-8F3E3EC0-6371-4E64-9F80-54557BD062D2Q34185105-2AA71E73-C47B-4226-859D-686BBA1F55DCQ35636206-A93F9205-A045-48B0-A26A-656CEE401C3DQ36059150-E58B029C-9519-45EF-8AEE-B9E166BE4C50Q36082891-0B6E4934-25D2-418F-BCF7-B86E5D5A5535Q36087129-CF4E9798-3F7F-48C9-B279-B31E271CB4F8Q36303185-466035F3-7EC5-44C8-9819-2E9F4A612507Q36352808-89342846-B5E1-49DF-89C3-F437C3ACEBA9Q36987584-C77AFFC4-FA1D-4285-94D3-6DE561F8EA81Q37604529-8DFD4560-5EEC-4096-95F8-C095658A213CQ37680028-4686F220-A5A9-448B-8E0C-4CF08ED8C8B6Q37944717-A64C6CA5-EFB3-48AA-9711-280E229ECED2Q38004886-A4D03443-91D5-4289-9FF9-4A8C01A50746Q38261504-9E200DC3-F5BE-42EC-A459-07C949E11214Q38434265-8BD9D2D3-AC21-4F85-8C68-26934DDAF69DQ38572340-D6D92B13-8198-47F3-ABB8-F3A8DCFC7C71Q38737317-3A5B9FA5-B9A6-4368-80EC-D0F4509BCDC9Q38785786-D755FD73-CE1E-4339-94F0-B39BFC1450BCQ38803597-355BD461-CAF6-4778-948D-E38F7783C534Q38829908-48787B1A-F933-468C-A3C0-423AAAC2680FQ38882993-720FB6C2-E1F9-4264-A73C-E9AB4085BBFFQ38981632-EFADE194-EFBA-401D-B9AE-112B69DE0ECFQ39200930-6B8B50F1-1FB6-4D11-AEF5-17351DEFDBACQ39238504-F0DAF4C8-09EF-4F10-98D6-6B8E0783AF47Q39248460-ED50EEC3-5F47-4830-987E-EC0CCEBCA023Q40053813-26529FB8-DFBE-45F3-8710-8F1A71C0E921Q40069289-4084BBC8-F184-405F-A1C6-EBB6526D5867Q40106877-FBDCCA06-FBC9-42DC-BC63-82FC2FFC1BD2Q40172547-BA5815F2-0E6B-4065-A07D-C81B7284D2B0Q40461222-85CAE8F0-6144-4454-BD61-6E63FD713BCDQ40680089-99C4FEFD-8F0B-4E90-8CF7-924F7AB7CD66Q41062630-FAD15C1A-0AFA-496B-9C72-78C1EAA8967AQ41564178-93F175ED-3BB2-4B0A-BFF9-409064747809
P2860
Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Clinical efficacy and cost-eff ...... rapy (OPAT): a UK perspective.
@en
type
label
Clinical efficacy and cost-eff ...... rapy (OPAT): a UK perspective.
@en
prefLabel
Clinical efficacy and cost-eff ...... rapy (OPAT): a UK perspective.
@en
P2093
P2860
P356
P1476
Clinical efficacy and cost-eff ...... rapy (OPAT): a UK perspective.
@en
P2093
Ann L N Chapman
Dawn Andrews
Julie D Patchett
Rohit Bazaz
P2860
P304
P356
10.1093/JAC/DKP343
P407
P577
2009-09-19T00:00:00Z